- A study in Frontiers of Medicine suggests a potential link between the inactivated COVID-19 vaccine CoronaVac (Sinovac Biotech) and immune thrombotic thrombocytopenic purpura (TTP), a rare blood disorder.
- It analyses two TTP cases and regional data indicating a rise in incidence after COVID-19 vaccination.
- While TTP is rare (approximately one new case per million annually), rates increased after COVID-19 vaccination campaigns.
- TTP is a rare, life-threatening blood disorder characterized by the formation of small clots that block blood flow to vital organs, causing fatigue, fever, bruising, bleeding, and kidney dysfunction.
- It is linked to a deficiency in the clot-regulating enzyme ADAMTS13, resulting from genetic mutations or autoimmune responses.
- COVID-19 vaccines may trigger autoimmune responses leading to ADAMTS13 deficiency, causing TTP development.
- A direct causal link between vaccination and TTP remains unconfirmed.
Dig Deeper: Read about rare autoimmune diseases.
